243 related articles for article (PubMed ID: 34045225)
1. Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects.
Ureshino H; Kurahashi Y; Watanabe T; Yamashita S; Kamachi K; Yamamoto Y; Fukuda-Kurahashi Y; Yoshida-Sakai N; Hattori N; Hayashi Y; Kawaguchi A; Tohyama K; Okada S; Harada H; Ushijima T; Kimura S
Mol Cancer Ther; 2021 Aug; 20(8):1412-1421. PubMed ID: 34045225
[TBL] [Abstract][Full Text] [Related]
2. Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion.
Chilakala S; Feng Y; Li L; Mahfouz R; Quteba E; Saunthararajah Y; Xu Y
Sci Rep; 2019 Mar; 9(1):4558. PubMed ID: 30872721
[TBL] [Abstract][Full Text] [Related]
3. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.
Mahfouz RZ; Jankowska A; Ebrahem Q; Gu X; Visconte V; Tabarroki A; Terse P; Covey J; Chan K; Ling Y; Engelke KJ; Sekeres MA; Tiu R; Maciejewski J; Radivoyevitch T; Saunthararajah Y
Clin Cancer Res; 2013 Feb; 19(4):938-48. PubMed ID: 23287564
[TBL] [Abstract][Full Text] [Related]
4. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
5. Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia.
Kamachi K; Ureshino H; Watanabe T; Yoshida-Sakai N; Fukuda-Kurahashi Y; Kawasoe K; Hoshiko T; Yamamoto Y; Kurahashi Y; Kimura S
Cancer Res Commun; 2023 Feb; 3(2):297-308. PubMed ID: 36860654
[TBL] [Abstract][Full Text] [Related]
6. Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism.
Yoshida-Sakai N; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Kimura S
Int J Cancer; 2022 Apr; 150(7):1184-1197. PubMed ID: 34913485
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
8. The development and clinical use of oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes: dawn of the total oral therapy era.
Schiffer M; Zhao J; Johnson A; Lee J; Bewersdorf JP; Zeidan AM
Expert Rev Anticancer Ther; 2021 Sep; 21(9):989-1002. PubMed ID: 33853476
[TBL] [Abstract][Full Text] [Related]
9. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
10. Clinical update on hypomethylating agents.
Duchmann M; Itzykson R
Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
[TBL] [Abstract][Full Text] [Related]
11. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
12. The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes.
Kipp D; H Wei A
Future Oncol; 2021 Jul; 17(20):2563-2571. PubMed ID: 33769069
[TBL] [Abstract][Full Text] [Related]
13. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T; Chinen T; Nishiyama A; Asada S; Shimura R; Isobe T; Yamamoto K; Sato N; Enomoto Y; Tanaka Y; Fukuyama T; Satoh H; Kato K; Saitoh K; Ishikawa T; Soga T; Nannya Y; Fukagawa T; Nakanishi M; Kitagawa D; Kitamura T; Goyama S
Cell Rep; 2023 Sep; 42(9):113098. PubMed ID: 37714156
[TBL] [Abstract][Full Text] [Related]
14. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
[TBL] [Abstract][Full Text] [Related]
15. Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells.
Geng S; Yao H; Weng J; Tong J; Huang X; Wu P; Deng C; Li M; Lu Z; Du X
Leuk Res; 2016 May; 44():17-24. PubMed ID: 26991610
[TBL] [Abstract][Full Text] [Related]
16. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.
Flotho C; Claus R; Batz C; Schneider M; Sandrock I; Ihde S; Plass C; Niemeyer CM; Lübbert M
Leukemia; 2009 Jun; 23(6):1019-28. PubMed ID: 19194470
[TBL] [Abstract][Full Text] [Related]
17. DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
Casellas Román HL; Venugopal K; Feng Y; Shabashvili DE; Posada LM; Li J; Guryanova OA
Leuk Res; 2020 Jul; 94():106372. PubMed ID: 32445940
[No Abstract] [Full Text] [Related]
18. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
19. A pilot pharmacokinetic study of oral azacitidine.
Garcia-Manero G; Stoltz ML; Ward MR; Kantarjian H; Sharma S
Leukemia; 2008 Sep; 22(9):1680-4. PubMed ID: 18548103
[TBL] [Abstract][Full Text] [Related]
20. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
